EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 609 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR CVS, Walgreens, Rite Aid Suspend Sales Of Zantac Following Cancer-Causing Concerns October 11, 2019 Coping With Life After a Bone Marrow Transplant: A Survivor’s Story August 15, 2023 ¿Qué deben saber las personas con cáncer sobre el consumo de... January 11, 2022 Addressing Cancer Pain with Complementary Methods (Part 1) April 7, 2023 Load more HOT NEWS Transforming optimism: finding new ways to treat rare cancers Death Rates from Lung Cancer will Fall Overall in the EU... Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor... Intensive Program Helps People Being Screened for Lung Cancer Quit Smoking
